We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis
News

Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis

Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis
News

Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Newly Published Data Shows Chronix Biomedicals’s Serum DNA Assays can Monitor Disease Activity and Treatment Response in Multiple Sclerosis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis (MS).  Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.  A growing body of publications from Chronix and other researchers shows that this circulating DNA can be identified and analyzed to provide a diagnostic window into ongoing changes in the genome associated with specific diseases—changes that can be used to track the presence or absence of active disease.  This new study is the first to show that the Chronix approach can be used to monitor the clinical status of a chronic disease.  The findings are published in the current online edition of the Journal of Molecular Diagnostics.*  
 
In the study, researchers applied advanced analytical techniques developed by Chronix to identify genomic DNA fingerprints in the bloodstream of 28 MS patients known to have relapsing or stable disease as compared to 50 healthy volunteers.  Researchers were able to distinguish the MS patients from the healthy volunteers and they also were able to use these circulating DNA fingerprints to differentiate periods of active disease attacks from the stable periods of disease remission characterizing relapsing-remitting MS, which affects about 85% of MS patients. 
   
The newly published MS data follows earlier work that demonstrated the ability of Chronix’s serum DNA-based assays to diagnose mad cow disease and chronic wasting disease in live animals, conditions that until now could only be diagnosed using post-mortem biopsies.  These successful studies in three neurological disorders suggest that when specialized nerve cells die, they leave behind unique DNA fingerprints characteristic of the cell of origin.  Chronix researchers have figured out how to identify and apply these unique fingerprints to diagnose disease and monitor disease activity.
 
“These positive data further support the Chronix approach to detecting and monitoring diseases, including neurologic diseases such as MS,” said Howard Urnovitz, Ph.D., Chief Executive Officer of Chronix.  “We are now preparing to offer laboratory testing services to support clinical trials for new neurologic drugs, initially focusing on MS and expanding to diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease and autism.  Eventually we intend to offer testing services that will allow physicians to monitor ongoing disease status and response to treatment in their patients with MS and other chronic neurological conditions.”
 
A publication in Molecular Cancer Research in March demonstrated the potential utility of the Chronix serum DNA assays in breast cancer.  The findings demonstrated that the Chronix approach was able to detect invasive breast cancer with high diagnostic sensitivity and specificity, even at the earliest stage when tumors are very small. 
 
Dr. Clerici is a member of the Chronix Medical Advisory Board and has an equity position in the company. Dr. Mitchell is an independent member of the Chronix Board of Directors and has an equity position in the company.
 
* “Serum DNA Motifs Predict Disease and Clinical Status in Multiple Sclerosis,” J Beck, H Urnovitz, M Saresella, D Caputo, M Clerici, M Mitchell, and E Schütz , J Mol Diag; 2010;12(5). Epub 12 Mar 2010

Advertisement